This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for LINK-HF2 - Remote Monitoring Analytics in Heart Failure (NCT04502563), a randomized na study. The primary outcome is Heart Failure Hospitalization Rate.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT04502563 |
| Phase | NA |
| Condition | Heart Failure |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Quadruple |
| Enrollment | 176 |
| Arms in the primary outcome | 2 |
| Lead sponsor | VA Office of Research and Development |
| Results posted | Yes |
2. Clinical Question
Population
People with heart failure were eligible for the study. The brief summary describes Veterans with heart failure, while the posted results identify 80.0 participants in the active arm and 91.0 in the control arm. The registry record lists enrollment as 176; its brief summary describes an intended enrollment of 240. The record does not explain the difference between those figures or provide further eligibility details.
Intervention
Participants in the active arm wore a sensor, with monitoring data analyzed by a predictive platform. Alerts indicating worsening heart failure were shared with the treating team, and an algorithmic response to alerts was implemented. The brief summary frames the approach as a way to identify possible worsening and inform care.
Comparator
Control participants also wore a sensor, but their sensor data did not generate alerts and were not shared with the treating team. The intervention list names this comparator as a sham comparator. The record does not provide further details about how the sham condition was implemented.
Primary question
The primary question was whether the 90-day heart failure hospitalization rate differed between the active and control arms. The posted outcome is a count of heart failure hospitalizations, with 13 in the active arm and 16 in the control arm. No statistical comparison, effect estimate, or uncertainty interval is reported in the registry record, so these counts alone do not establish whether the arms differed beyond the observed values.
3. Trial Design
LINK-HF2 is listed as a randomized, parallel-group study with quadruple masking. The registry record labels the phase as NA. The sponsor is the VA Office of Research and Development. The study status is completed, with a start date of 2021-04-19 and a primary completion date of 2024-08-31.
The two arms compared remote monitoring and predictive analytics with a control condition. In the active arm, participants wore a sensor; data were analyzed on a predictive platform; alerts for possible heart failure worsening were shared with the treating team; and an algorithmic response to alerts was implemented. Control participants wore a sensor, but their data did not generate alerts or reach the treating team. The interventions are both classified as other in the registry record.
The record lists 176 participants enrolled. The brief summary describes a plan to enroll 240 Veterans and randomly assign half to monitoring and communication of information to their medical teams. It does not explain the difference between the planned figure and the recorded enrollment. Posted primary-outcome arm counts are based on 80.0 participants in the active arm and 91.0 in the control arm. The registry record does not explain the relationship between these arm counts and overall enrollment.
The brief summary describes an interest in hospital admissions, length of hospital stay, and quality of life. The posted secondary-outcome list names the Kansas City Cardiomyopathy Questionnaire Score. Details about randomization procedures, the roles covered by masking, allocation concealment, and the analysis population are not reported in the registry record.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Overall Study
| Stage | Active Arm | Control |
|---|---|---|
| STARTED | 85 | 91 |
| COMPLETED | 80 | 91 |
| NOT COMPLETED | 5 | 0 |
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Active Arm | Control | Total |
|---|---|---|---|---|
| Participants analysed | 80 | 91 | 171 | |
| Age, Continuous | years | 72.4 (SD 9.5) | 72.8 (SD 11.9) | 72.6 (SD 10.7) |
| Sex: Female, Male: Female | Participants | 3 | 3 | 6 |
| Sex: Female, Male: Male | Participants | 77 | 88 | 165 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 2 | 1 | 3 |
| Race (NIH/OMB): Asian | Participants | 0 | 1 | 1 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 1 | 2 | 3 |
| Race (NIH/OMB): Black or African American | Participants | 21 | 16 | 37 |
| Race (NIH/OMB): White | Participants | 56 | 71 | 127 |
| Race (NIH/OMB): More than one race | Participants | 0 | 0 | 0 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 |
| Ethnicity (NIH/OMB): Hispanic or Latino | Participants | 1 | 6 | 7 |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | Participants | 77 | 85 | 162 |
| Ethnicity (NIH/OMB): Unknown or Not Reported | Participants | 2 | 0 | 2 |
| Body Mass Index | Kg/m^2 | 31.6 (SD 8.2) | 31.0 (SD 6.5) | 31.3 (SD 7.4) |
| Heart failure with reduced ejection fraction | Participants | 47 | 59 | 106 |
| Heart failure with preserved ejection fraction | Participants | 33 | 32 | 65 |
| New York Heart Association Class: I | Participants | 0 | 0 | 0 |
| New York Heart Association Class: II | Participants | 53 | 61 | 114 |
| New York Heart Association Class: III | Participants | 26 | 26 | 52 |
| New York Heart Association Class: IV | Participants | 1 | 4 | 5 |
| Heart Failure Etiology: Ischemic | Participants | 43 | 48 | 91 |
| Heart Failure Etiology: Non-ischemic | Participants | 37 | 43 | 80 |
| Hypertension | Participants | 59 | 72 | 131 |
| Hyperlipidemia | Participants | 56 | 51 | 107 |
| Diabetes Mellitus | Participants | 45 | 51 | 96 |
| Sleep Apnea | Participants | 34 | 50 | 84 |
| Atrial Fibrillation | Participants | 40 | 43 | 83 |
6. Primary Endpoint
The registry lists the primary outcome as Heart Failure Hospitalization Rate, measured over 90 days.
| Element | Registry entry |
|---|---|
| Result type | Number |
| Measure of spread | not applicable |
| Unit | Heart failure hospitalizations |
| Endpoint classification | not reduced to a single comparison |
The primary endpoint is titled Heart Failure Hospitalization Rate and is described as the 90-day hospitalization rate in the active arm versus the control arm. Its unit is heart failure hospitalizations, and its parameter is listed as a number. The posted values are 13 hospitalizations for the active arm and 16 for the control arm.
Hospitalization is a clinically meaningful outcome for a study aimed at detecting worsening heart failure and communicating alerts to care teams. Counting hospitalizations can capture repeated events, unlike an outcome that records only whether each participant had at least one event. However, the registry record does not clarify whether each participant could contribute multiple hospitalizations, how events were defined or adjudicated, or how follow-up time was handled for participants with incomplete observation.
The endpoint title uses the word “rate,” but the posted results provide counts and arm sizes without an exposure-time denominator, rate estimate, or adjusted comparison. The numbers therefore describe the recorded event totals, not a calculated rate or a treatment-effect estimate. The registry record does not report an uncertainty interval or inferential test for this endpoint.
In general, a count endpoint is useful when the number of events matters, but its analysis needs to account for the distribution of events and the observation period. The specific model and assumptions used for LINK-HF2 are not reported in the registry record.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The posted primary results are 13 heart failure hospitalizations in the active arm and 16 in the control arm, with arm sizes of 80.0 and 91.0, respectively. These are raw event counts. They do not, by themselves, quantify the uncertainty around the difference between arms or show whether an observed contrast is compatible with chance variation.
The outcome is described as a 90-day hospitalization rate, but the registry record reports a number of hospitalizations rather than a rate per person-time or a model-based rate comparison. It gives no confidence interval, p-value, adjusted estimate, or other inferential result for the primary outcome. The registry record therefore does not establish the statistical strength or precision of a between-arm effect. The counts should be read as descriptive results, not as evidence of a statistically significant difference.
The count total is not the same as the number of participants hospitalized. A participant may potentially contribute more than one event to a count outcome, but whether that occurred and how repeat hospitalizations were handled are not reported in the registry record. No conclusion about the number of people who experienced any hospitalization can be drawn from these totals alone.
The registry record lists 176 participants enrolled, while the brief summary describes an intended enrollment of 240. The posted arm sizes are 80.0 and 91.0. The record does not explain the difference between the intended enrollment, recorded enrollment, and arm sizes used for the posted endpoint values. It also does not report an analysis population or a participant flow that would explain which participants contributed to the outcome.
There are no posted inferential analyses among the registry entries described for this study. The record identifies one secondary outcome, the Kansas City Cardiomyopathy Questionnaire Score, but does not give its results in the available information. Thus, neither a comparison of quality-of-life scores nor a broader evaluation across outcomes can be described. The brief summary's aims concerning hospital stays and quality of life should not be mistaken for posted findings.
The study was randomized, which can support a fair comparison when allocation and analysis are properly conducted. Randomization alone does not resolve the limitations of a descriptive result: interpretation still depends on outcome definitions, follow-up, analysis methods, missing data, and precision. Those details are not reported in the registry record. The primary result is therefore limited to the observed event counts and the stated 90-day timeframe.
9. Statistical Methods Explained
Statistical interpretation depends on how the outcome is defined, what participants contribute data, and how the comparison is analyzed. The registry record describes a randomized, parallel-group study and a count endpoint over 90 days, but does not report the statistical analysis plan or an inferential result. The following concepts are general explanations; the specific methods used for LINK-HF2 are not reported in the registry record.
What does randomization contribute?
In general, random assignment aims to make the groups comparable at the outset with respect to both measured and unmeasured characteristics. This supports estimating the effect of assignment to one study strategy rather than another. Randomization does not guarantee that the resulting groups are identical, especially in a finite study, and it does not replace transparent reporting of the allocation process, participant flow, or analysis population. Details of the randomization method and allocation concealment are not reported in the registry record.
The study is labeled quadruple masked, but the registry record does not specify which people or roles were masked. It also does not describe how masking was maintained or assessed. The control group wore a sensor whose data did not generate alerts or reach the treating team. These design details describe the comparator, but the record does not establish how participants or staff understood the group assignments.
How should a count outcome be analyzed?
In general, count outcomes can be analyzed with methods designed for nonnegative event totals. A comparison might estimate an event rate or a ratio of rates, or it might estimate another contrast selected in the analysis plan. The appropriate method depends on the estimand, the event distribution, exposure time, and whether events from one participant are correlated. The posted arm counts do not identify which contrast or model was used.
Over-dispersion is a general concern for count data. It occurs when event counts vary more than a model assumes, which can make standard errors too small if the model does not accommodate that variation. Repeated events from the same participant can also be statistically related. General approaches may account for these features, but the registry record does not report whether repeat events were included, what distribution was assumed, or whether over-dispersion was assessed.
The endpoint title calls the outcome a hospitalization rate, while the posted values are total counts. A rate requires an appropriate denominator representing time at risk or observation. Without a reported denominator and a specified calculation, the two totals cannot be converted into rate estimates or compared as rates. No recalculated rate or effect estimate is reported in the registry record.
What does uncertainty reporting add?
In general, a confidence interval describes a range of values compatible with the data and the assumptions of the analysis. It conveys precision as well as direction and magnitude. A p-value, when reported, addresses how unusual data at least as incompatible with a specified null hypothesis would be under that hypothesis and model. Neither measure is a substitute for a clear effect estimate, and neither alone establishes clinical importance.
For LINK-HF2, the registry record does not report a confidence interval, p-value, or model-based comparison for the primary outcome. The displayed counts therefore cannot support a claim about statistical significance, precision, or the magnitude of a population-level effect. The record does not provide enough information to reconstruct an appropriate inferential analysis from the counts alone.
What can planning calculations tell readers?
In general, sample-size planning calculations describe the number of participants that may be needed under stated assumptions about the target effect, statistical threshold, allocation, and analysis method. They are planning illustrations, not observed results, and they are not a measure of the probability that a completed study has detected a true effect. When planning is based on an effect observed in the same study, the assumptions should be interpreted cautiously because an observed effect can be imprecise.
The registry record describes a planning approach using a two-sided significance level of 0.05, equal allocation, and a normal approximation, with the target effect expressed as a fraction of the observed effect. It also distinguishes calculations for time-to-event outcomes from other outcomes. Numerical planning estimates and a study-specific design justification are not reported in the registry record. The record does not say that these planning assumptions were the protocol's original design assumptions.
No statistical analysis plan, named count-data model, adjustment strategy, or outcome-specific inferential method is reported in the registry record. Accordingly, methodological explanations should be treated as general context, not as a description of analyses confirmed to have been conducted for this trial.
10. Multiplicity, Missing Data and Analysis Populations
The registry record names the Kansas City Cardiomyopathy Questionnaire Score as a secondary outcome and lists two outcome measures. It reports no analyses for the listed outcomes in the available record. Results for the secondary outcome, including its arm-specific values and any comparison, are not reported in the registry record.
Multiplicity arises when several outcomes or analyses are considered, because each additional test can affect the chance of at least one apparently unusual result. In general, investigators may identify one primary outcome in advance, use a hierarchy, or apply an adjustment. The registry record does not report a multiplicity strategy, outcome hierarchy beyond identifying the primary endpoint, or a statistical analysis plan. It is therefore not possible to determine how multiple outcomes or analyses were to be interpreted.
Missing-data methods and analysis populations are also not reported in the registry record. The record does not say whether the primary analysis was intended to include all randomized participants, only participants with available endpoint data, or another defined group. It does not describe missing outcome data, reasons for missingness, censoring, imputation, or sensitivity analyses. The relationship among the enrollment figure, posted arm sizes, and endpoint counts is not explained.
These omissions limit assessment of the analysis and its potential biases. They do not establish that data were missing or that an analysis was not performed; they mean the relevant details are not reported in the registry record.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Active Arm | 0 | 85 | 0.0% |
| Control | 0 | 91 | 0.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Active Arm | 3 of 85 |
| Control | 2 of 91 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 0% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Active Arm | 0 of 85 |
| Control | 0 of 91 |
The posted safety figures report zero participants with serious adverse events among 85 at risk in the active arm and zero among 91 at risk in the control arm. Other adverse events are likewise reported as zero among 85 and 91 participants at risk, respectively. Deaths are reported separately: 3 in the active arm and 2 in the control arm.
These are descriptive counts. The record does not provide details of event definitions, observation duration for safety reporting, event attribution, or an inferential comparison. The safety denominators also differ from the primary-outcome arm sizes, which are listed as 80.0 and 91.0; the registry record does not explain the difference. Zero recorded serious events in these summaries should not be interpreted as proof that no serious events occurred outside the reported scope or that the risks are equivalent.
Deaths are a separate safety figure and should not be assumed to be caused by the study intervention. The registry record does not provide causes or attribution for the deaths, or enough detail to compare safety between arms. These numbers alone do not establish a safety difference.
12. What the Result Does, and Does Not, Mean
The posted results establish that the registry record contains a randomized comparison of remote monitoring and predictive analytics with a sensor-based control condition, and that the primary endpoint was framed around heart failure hospitalizations over 90 days. The recorded event totals are 13 in the active arm and 16 in the control arm. These observations are descriptive and should be interpreted in that limited way.
The counts do not show how many participants had at least one hospitalization, whether any participant had repeated hospitalizations, or how event totals were distributed across participants. They also do not provide an adjusted or unadjusted effect estimate, an uncertainty interval, or a test of the difference. The registry record does not report the analysis method, event adjudication details, or the handling of incomplete follow-up. Without those details, the counts cannot establish the size or precision of a population-level effect.
The results do not show that the monitoring strategy changed treatment, prevented hospitalization, shortened hospital stays, or improved quality of life. Those aims appear in the brief summary, but the posted information does not include corresponding inferential findings. The named secondary outcome is a Kansas City Cardiomyopathy Questionnaire Score, but its results are not reported in the registry record.
The safety entries report no serious adverse events or other adverse events in the listed at-risk groups, alongside separately recorded deaths. These summaries are not a complete causal safety assessment, and the registry record does not report an arm comparison for safety. The death counts cannot be attributed to the intervention from the information reported.
Overall, the record supports a narrow conclusion about what was posted: two arm-specific hospitalization counts and descriptive safety figures. It does not support a claim of benefit, lack of benefit, statistical significance, equivalence, or a definitive safety conclusion.
13. Why This Trial Matters Statistically
This study is statistically interesting because it evaluates a monitoring strategy whose intended pathway includes detecting possible worsening heart failure and communicating alerts to treating teams. That pathway combines a sensor, predictive analytics, and clinical response. A randomized comparison can help distinguish the consequences of assignment to that strategy from outcomes under a sensor condition without alert communication, provided the design and analysis are fully reported.
The primary endpoint is a count of hospitalizations over a stated 90-day period. Count outcomes raise questions that do not arise in the same way for a simple yes-or-no endpoint: whether repeat events are included, whether participants have equal observation time, and how within-participant clustering and variation in event counts are handled. The record gives event totals but does not report these analytic details or a statistical comparison. That gap illustrates why outcome labels and raw totals are not enough to interpret a trial result.
The record also distinguishes an intended enrollment in the brief summary from the enrollment recorded for the completed study, without explaining the difference. Readers need clear participant flow and analysis populations to understand which participants contributed to each result. Differences between the posted arm sizes and safety denominators add to the need for transparent accounting.
Finally, the study lists a quality-of-life measure and safety outcomes, but the available record does not provide inferential results for them. A complete statistical interpretation requires more than a primary endpoint count: it depends on prespecified analyses, uncertainty estimates, missing-data handling, and a coherent account of all planned outcomes. The posted record offers a useful description of the trial question, but leaves those elements unresolved.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The primary endpoint is named as a hospitalization rate, yet the posted result is a count in each arm. No denominator based on time at risk, rate estimate, effect measure, confidence interval, or p-value is reported. This prevents assessment of the magnitude and precision of the primary comparison.
The registry record does not describe the hospitalization definition, event adjudication, treatment of repeat admissions, or follow-up completeness. It also does not report how missing outcome information or unequal observation time was handled. These omissions matter for a count endpoint because both event capture and time under observation can affect the totals.
The record lists enrollment as 176, while the brief summary describes an intended enrollment of 240. The posted primary-outcome arm sizes are 80.0 and 91.0, and the safety denominators are 85 and 91. The record does not reconcile these figures or provide participant flow, reasons for exclusions, or analysis-population definitions.
Although the study is described as randomized and quadruple masked, the registry record does not provide the randomization procedure, the roles covered by masking, or details about maintaining masking. It does not report the analysis plan, a model for count data, multiplicity handling, missing-data methods, or a protocol-specific sample-size justification.
The secondary outcome is named but its results are not reported in the registry record. The safety summaries are descriptive, with no event definitions or inferential comparison, and the deaths are not characterized by cause or attribution. These limitations constrain what can be inferred from the posted record; they do not establish that the unreported procedures or analyses were absent.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: LINK-HF2 - Remote Monitoring Analytics in Heart Failure — NCT04502563.
- Registry record last updated 2026-04-28; status last verified 2026-04.
- Results first posted 2026-04-28.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
LINK-HF2 is a completed randomized, parallel-group study of remote monitoring and predictive analytics in heart failure, sponsored by the VA Office of Research and Development. The record lists quadruple masking and a study phase of NA. Its start date is 2021-04-19, and its primary completion date is 2024-08-31.
The active arm used sensor monitoring, predictive analysis, and alerts shared with the treating team; the control arm wore a sensor without alert generation or communication to the team. The primary outcome was heart failure hospitalizations over 90 days. Posted counts are 13 in the active arm and 16 in the control arm, with arm sizes of 80.0 and 91.0. No inferential comparison is reported in the registry record.
The record lists the Kansas City Cardiomyopathy Questionnaire Score as a secondary outcome but does not report its results. Safety entries report zero serious adverse events in both at-risk groups and 3 deaths in the active arm and 2 in the control arm. Statistical methods, missing-data handling, analysis populations, and explanations for differences among enrollment and outcome denominators are not reported in the registry record.